Cargando…
A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats
BACKGROUND: Oclacitinib is a Janus kinase (JAK) 1 enzyme inhibitor and blocks JAK1-dependent cytokines and is used to control pruritus. Studies available in cats are very limited and as there is a potential role for oclacitinib in the control of pruritus in this specie, the aim of this study was to...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506962/ https://www.ncbi.nlm.nih.gov/pubmed/31068210 http://dx.doi.org/10.1186/s12917-019-1893-x |
_version_ | 1783416943818047488 |
---|---|
author | Lopes, Natália Lôres Campos, Diefrey Ribeiro Machado, Marília Alves Alves, Mariana Silva Revoredo de Souza, Manuela Silva Gomes da Veiga, Cristiano Chaves Pessoa Merlo, Alexandre Scott, Fábio Barbour Fernandes, Julio Israel |
author_facet | Lopes, Natália Lôres Campos, Diefrey Ribeiro Machado, Marília Alves Alves, Mariana Silva Revoredo de Souza, Manuela Silva Gomes da Veiga, Cristiano Chaves Pessoa Merlo, Alexandre Scott, Fábio Barbour Fernandes, Julio Israel |
author_sort | Lopes, Natália Lôres |
collection | PubMed |
description | BACKGROUND: Oclacitinib is a Janus kinase (JAK) 1 enzyme inhibitor and blocks JAK1-dependent cytokines and is used to control pruritus. Studies available in cats are very limited and as there is a potential role for oclacitinib in the control of pruritus in this specie, the aim of this study was to evaluate the safety and clinical effects of oral oclacitinib maleate in healthy cats. RESULTS: Thirty mixed-breed cats weighing from 2.1 to 5.3 kg each were randomly allocated to three treatment groups of 10 animals each. Cats in two groups received oclacitinib at 1 mg/kg or 2 mg/kg q 12 h orally for 28 days. Cats in the third group were given placebo tablets (cornstarch) q 12 h orally for 28 days. Oclacitinib maleate was well tolerated during the study and few adverse events were observed in treated cats. Clinical signs of toxicity were not observed in any animals treated at 1 mg/kg. Gastrointestinal clinical signs observed in the 2 mg/kg group included vomiting in two of the 10 cats and soft stools in two cats. One cat treated with placebo also exhibited soft stools. No significant differences were observed between the groups for hematologic analyses performed during the study. There was a slight increase in neutrophils and monocytes and a decrease in eosinophil mean counts in treated cats. Mean renal and liver enzymes remained normal throughout the entire study. A small, but significant increase in fructosamine levels was observed for both treated groups compared with placebo; however, values remained within the normal reference range. There were no significant difference between treated groups and the placebo group for urine specific gravity, pH, or urine protein to creatinine ratio mean values. CONCLUSIONS: Oclacitinib maleate was well tolerated by cats at 1 mg/kg and 2 mg/kg and appeared to be safe for this species when administered orally twice daily for 28 days. More studies would be needed to demonstrate if oclacitinib maleate may be a suitable alternative to treat pruritic cats. |
format | Online Article Text |
id | pubmed-6506962 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-65069622019-05-13 A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats Lopes, Natália Lôres Campos, Diefrey Ribeiro Machado, Marília Alves Alves, Mariana Silva Revoredo de Souza, Manuela Silva Gomes da Veiga, Cristiano Chaves Pessoa Merlo, Alexandre Scott, Fábio Barbour Fernandes, Julio Israel BMC Vet Res Research Article BACKGROUND: Oclacitinib is a Janus kinase (JAK) 1 enzyme inhibitor and blocks JAK1-dependent cytokines and is used to control pruritus. Studies available in cats are very limited and as there is a potential role for oclacitinib in the control of pruritus in this specie, the aim of this study was to evaluate the safety and clinical effects of oral oclacitinib maleate in healthy cats. RESULTS: Thirty mixed-breed cats weighing from 2.1 to 5.3 kg each were randomly allocated to three treatment groups of 10 animals each. Cats in two groups received oclacitinib at 1 mg/kg or 2 mg/kg q 12 h orally for 28 days. Cats in the third group were given placebo tablets (cornstarch) q 12 h orally for 28 days. Oclacitinib maleate was well tolerated during the study and few adverse events were observed in treated cats. Clinical signs of toxicity were not observed in any animals treated at 1 mg/kg. Gastrointestinal clinical signs observed in the 2 mg/kg group included vomiting in two of the 10 cats and soft stools in two cats. One cat treated with placebo also exhibited soft stools. No significant differences were observed between the groups for hematologic analyses performed during the study. There was a slight increase in neutrophils and monocytes and a decrease in eosinophil mean counts in treated cats. Mean renal and liver enzymes remained normal throughout the entire study. A small, but significant increase in fructosamine levels was observed for both treated groups compared with placebo; however, values remained within the normal reference range. There were no significant difference between treated groups and the placebo group for urine specific gravity, pH, or urine protein to creatinine ratio mean values. CONCLUSIONS: Oclacitinib maleate was well tolerated by cats at 1 mg/kg and 2 mg/kg and appeared to be safe for this species when administered orally twice daily for 28 days. More studies would be needed to demonstrate if oclacitinib maleate may be a suitable alternative to treat pruritic cats. BioMed Central 2019-05-08 /pmc/articles/PMC6506962/ /pubmed/31068210 http://dx.doi.org/10.1186/s12917-019-1893-x Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Lopes, Natália Lôres Campos, Diefrey Ribeiro Machado, Marília Alves Alves, Mariana Silva Revoredo de Souza, Manuela Silva Gomes da Veiga, Cristiano Chaves Pessoa Merlo, Alexandre Scott, Fábio Barbour Fernandes, Julio Israel A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats |
title | A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats |
title_full | A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats |
title_fullStr | A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats |
title_full_unstemmed | A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats |
title_short | A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats |
title_sort | blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506962/ https://www.ncbi.nlm.nih.gov/pubmed/31068210 http://dx.doi.org/10.1186/s12917-019-1893-x |
work_keys_str_mv | AT lopesnatalialores ablindedrandomizedplacebocontrolledtrialofthesafetyofoclacitinibincats AT camposdiefreyribeiro ablindedrandomizedplacebocontrolledtrialofthesafetyofoclacitinibincats AT machadomariliaalves ablindedrandomizedplacebocontrolledtrialofthesafetyofoclacitinibincats AT alvesmarianasilvarevoredo ablindedrandomizedplacebocontrolledtrialofthesafetyofoclacitinibincats AT desouzamanuelasilvagomes ablindedrandomizedplacebocontrolledtrialofthesafetyofoclacitinibincats AT daveigacristianochavespessoa ablindedrandomizedplacebocontrolledtrialofthesafetyofoclacitinibincats AT merloalexandre ablindedrandomizedplacebocontrolledtrialofthesafetyofoclacitinibincats AT scottfabiobarbour ablindedrandomizedplacebocontrolledtrialofthesafetyofoclacitinibincats AT fernandesjulioisrael ablindedrandomizedplacebocontrolledtrialofthesafetyofoclacitinibincats AT lopesnatalialores blindedrandomizedplacebocontrolledtrialofthesafetyofoclacitinibincats AT camposdiefreyribeiro blindedrandomizedplacebocontrolledtrialofthesafetyofoclacitinibincats AT machadomariliaalves blindedrandomizedplacebocontrolledtrialofthesafetyofoclacitinibincats AT alvesmarianasilvarevoredo blindedrandomizedplacebocontrolledtrialofthesafetyofoclacitinibincats AT desouzamanuelasilvagomes blindedrandomizedplacebocontrolledtrialofthesafetyofoclacitinibincats AT daveigacristianochavespessoa blindedrandomizedplacebocontrolledtrialofthesafetyofoclacitinibincats AT merloalexandre blindedrandomizedplacebocontrolledtrialofthesafetyofoclacitinibincats AT scottfabiobarbour blindedrandomizedplacebocontrolledtrialofthesafetyofoclacitinibincats AT fernandesjulioisrael blindedrandomizedplacebocontrolledtrialofthesafetyofoclacitinibincats |